

06-13-2001



101748354

Substitute Form PTO-1595

Attorney Docket Number: 07891/001001

Certificate of Mailing: Date of Deposit June 5, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to BOX ASSIGNMENT, Commissioner, United States Patent and Trademark Office, Washington, D.C. 20231.

Mary Jane DiPalma

Printed Name

Signature of Person Mailing Correspondence

RECORDATION FORM COVER SHEET PATENTS ONLY

Please record the attached document.

1. Names of all conveying parties: Apoptogen Inc. 401 Smyth Road Ottawa, Ontario K1H 8L1 CANADA Additional names attached: NO	2. Names and addresses of all receiving parties: AEGERA Therapeutics Inc. 810 Chemin du Golf Verdun, Qubec H3E 1A8 CANADA Additional names/addresses attached: NO
3. Nature of conveyance: ☐ Assignment ☒ Merger ☐ Security Agreement ☐ Change of Name ☐ Other: _____ Execution Date: May 19, 2000	
4. Application numbers or patent numbers: A. Patent Application Numbers: 09/011,356; 09/201,936; 09/201,932; 09/617,053; 09/616,614; and 09/743,347	B. Patent Numbers: 6,133,437; 6,107,041; 6,107,088; 6,159,709; and 6,171,821
5. Name and address of party to whom correspondence concerning document should be mailed: Kristina Bieker-Brady, Ph.D., Reg. No. 39,109 Clark & Elbing LLP 176 Federal Street Boston, MA 02110 Customer No.: 21559	6. Total number of applications/patents involved: 11 7. Total fee (37 C.F.R. § 3.41): \$440.00 ☒ \$440.00 Fee enclosed ☐ Authorized to charge deposit account 8. Deposit account number: 03-2095. If the fee above is being charged to deposit account, a duplicate copy of this cover sheet is attached. Please apply any additional charges, or any credits, to Deposit Account No. 03-2095.

DO NOT USE THIS SPACE

9. Statement and signature: *To the best of my knowledge and belief, the foregoing information is true and correct and the attached is the original document.*

Kristina Bieker-Brady, Ph.D.

Signature

KAREL ELBING
REG NO 35,238

5 June 2001
Date

02/21/2001

14:15

AEGERA THERAPEUTICS → 16174287045

06/19/00

17:13 FAX 8132308842

BORDEN LADNER GERRYVAIS

NO. 726 0002

MAY 19 2000



Industry Canada

Industrie Canada

**Certificate
of Amalgamation****Canada Business
Corporations Act****Certificat
de fusion****Loi canadienne sur
les sociétés par actions****AEGERA THERAPEUTICS INC./****AEGERA THÉRAPEUTIQUE INC.****377573-9**

Name of corporation-Dénomination de la société

Corporation number-Numéro de la société

I hereby certify that the above-named corporation resulted from an amalgamation, under section 185 of the *Canada Business Corporations Act*, of the corporations set out in the attached articles of amalgamation.

Je certifie que la société susmentionnée est issue d'une fusion, en vertu de l'article 185 de la *Loi canadienne sur les sociétés par actions*, des sociétés dont les dénominations apparaissent dans les statuts de fusion ci-joints.

Director - Directeur

May 19, 2000 / le 19 mai 2000

Date of Amalgamation - Date de fusion

Canada

02/21/2001

14:15

AEGERA THERAPEUTICS → 16174287045

05/19/00 17:13 FAX 8132308842

BUREAU LAUREN VICTORIA

NO. 726 0003



Industry Canada

Industrie Canada

Canada
BusinessLoi canadienne sur les
sociétés par actionsFORM 9
ARTICLES OF AMALGAMATION
(SECTION 185)FORMULE 9
STATUTS DE FUSION
(ARTICLE 185)

1 - Name amalgamated corporation
AEGERA THERAPEUTICS INC./AEGERA THÉRAPEUTIQUE INC.

2 - The place in Canada where the registered office is
to be situated
Greater Montreal Region, Province of Quebec

3 - The classes and any maximum number of shares that
the corporation is authorized to issue
See attached Schedule "A".

4 - Restrictions, if any, on share transfers
See attached Schedule "B".

5 - Number (or minimum and maximum number) of directors
A minimum of three (3) and a maximum of eleven (11).

6 - Restrictions, if any, on business the corporation may carry on
None.

7 - Other provisions, if any
See attached Schedule "C".

8 - The amalgamation has been approved pursuant to that
section or subsection of the Act which is indicated as follows:

8 - La fusion a été approuvée en accord avec l'article ou le
paragraphe de la Loi indiqué ci-après

☒ 183☐ 184(1)☐ 184(2)

9 - Name of the amalgamating corporations Dénomination des sociétés fusionnantes	Corporation No. N° de la société	Signature	Date	Title Titre
APOPTOGEN INC.	316690-2	<i>[Signature]</i>	May 16 /00	CEO
EXOGEN NEUROSCIENCES INC.	326430-1	<i>[Signature]</i>	May 16/00	CEO

02/21/2001

14:15

AEGERA THERAPEUTICS → 16174287045

06/19/00

17:13 FAX 6132308842

BORDEN LADNER GERVAIS

NO. 726 0004
0004/005

SCHEDULE "B"

4 - Restrictions on share transfers

Subject to the terms of any share issue or transfer restrictions in a shareholder agreement, the right to transfer shares in the capital stock of the Corporation is restricted and no shares of the Corporation shall be transferred without the consent of the Board of Directors first being obtained.

LG-OTT-1 / 58833